Compare Johnson & Johnson (JNJ) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Quantumscape Corp — how do they compare? Johnson & Johnson trades at $256.22 (market cap $618.09B), while Quantumscape Corp trades at $4.7 (market cap $2.82B). The key difference: Johnson & Johnson is far larger — about 219.2× Quantumscape Corp's market cap, and Johnson & Johnson pays a 2.09% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Quantumscape Corp for 37 Days on average.
| JNJ | QS | |
|---|---|---|
Market Cap | $618.09B | $2.82B |
Volume | 6,050,983 | 21,878,246 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $18.44 |
52-Week Low | $186.00 | $4.52 |
Typical Hold Time | 129 Days | 37 Days |
Enterprise Value | $646.37B | $2.03B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
QuantumScape (QS) trades at $4.52, down 2.8% on the day, reflecting ongoing investor skepticism about the solid-state battery developer's path to commercialization. The stock shows bearish technical signals with negative moving averages and oscillators, while fundamental challenges persist with zero revenue, negative EBITDA of -$358.25M (2025), and consecutive quarterly losses. Recent news highlights commercialization delays and insider selling, though the company continues ramping pilot production lines for automotive and new market applications.
The outlook remains high-risk with commercialization not expected until 2029, creating significant execution and competitive threats. While the consensus price target of $10.35 suggests potential upside from current levels, analyst sentiment is cautious with 73% hold ratings. Investment opportunity exists only for speculative investors comfortable with pre-revenue developmental stage risks and extended timelines to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
